AURA

Aura Biosciences, Inc. (AURA) - 10-K Summary

Business Context and Reporting Period

Company: Aura Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Aura is a clinical-stage biotechnology company developing precision therapies to treat solid tumors with a focus on preserving organ function. The company's lead product candidate, bel-sar (belzupacap sarotalocan), is a Virus-Like Drug Conjugate (VDC) currently in late-stage clinical development for early choroidal melanoma (eye cancer) and non-muscle invasive bladder cancer (NMIBC). The company has no approved products and has not generated any revenue to date.

Key Financial Metrics

Note: The company reported no debt or long-term liabilities other than operating lease obligations.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $19.3 million (22%) year-over-year, driven primarily by higher R&D expenses.
• R&D Expense Growth: R&D expenses rose by $17.0 million (23%) to $90.3 million. This increase was attributed to ongoing clinical and CRO costs associated with the global Phase 3 CoMpass trial for early choroidal melanoma and higher personnel expenses.
• Financing Activity: In May 2025, the company completed a Follow-On Offering raising approximately $69.9 million in net proceeds. Additionally, the company raised $6.7 million through At-The-Market (ATM) offerings during 2025.
• Interest Income Decline: Interest income decreased by $2.8 million to $6.6 million, reflecting changes in marketable securities and interest rates.

Guidance, Outlook, and Risks

Going Concern Warning: The company's independent auditors have issued a "going concern" opinion. Management has determined there is substantial doubt about the company's ability to continue as a going concern for twelve months following the filing date due to recurring losses and the need for additional capital to fund operations.

Clinical Outlook:

• Early Choroidal Melanoma: The global Phase 3 CoMpass trial is ongoing. Enrollment is expected to be completed by mid-2026, with topline data anticipated in the second half of 2027.
• Bladder Cancer (NMIBC): A Phase 1b/2 trial is ongoing. Initial three-month clinical data is expected in mid-2026.
• Other Indications: Phase 2 trials for metastases to the choroid and Phase 1 proof-of-concept trials for cancers of the ocular surface are underway or initiating.

Key Risks:

• Capital Requirements: The company requires substantial additional funding to complete clinical trials and commercialization. Failure to raise capital could force delays or termination of programs.
• Regulatory Approval: Success depends entirely on the approval of bel-sar. The FDA has agreed to a Special Protocol Assessment (SPA) for the Phase 3 trial, but this does not guarantee approval.
• Single Product Dependence: The business is heavily dependent on the success of bel-sar, its only product candidate.
• Third-Party Reliance: The company relies on third-party CDMOs for manufacturing and CROs for clinical trials.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $144.2 million cash balance against the projected burn rate to fund the Phase 3 trial completion and potential commercialization.
• Phase 3 Enrollment: Monitor the progress of patient enrollment in the CoMpass trial, as delays could push data readout beyond 2027.
• Capital Raising Plans: Review upcoming financing activities (equity, debt, or partnerships) required to address the "going concern" uncertainty.
• Manufacturing Scale-Up: Assess the status of transferring manufacturing processes from clinical to commercial scale with CDMOs.
• Intellectual Property: Confirm the status of patent families covering bel-sar, noting expiration dates ranging from 2028 to 2046.